We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Evraz Plc | LSE:EVR | London | Ordinary Share | GB00B71N6K86 | ORD USD0.05 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 82.68 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
EVRAZ plc (EVR) EVRAZ plc announces that the Appointment and the Amendments adopted as part of the Consent Solicitation for its outstanding notes due 2023 have become effective 19-Dec-2022 / 14:00 MSK Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
-----------------------------------------------------------------------------------------------------------------------
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT OR THE CONSENT SOLICITATION MEMORANDUM.
EVRAZ plc announces that the Appointment and the Amendments adopted as part of the Consent Solicitation for its outstanding U.S.USD750,000,000 5.375 per cent. notes due 2023 have become effective
London, 19 December 2022 - on 15 November 2022, EVRAZ plc (the "Issuer") announced a consent solicitation in relation to the outstanding U.S.USD750,000,000 5.375 per cent. notes due 2023 issued by the Issuer (Regulation S Notes: Common Code 153391572 / ISIN XS1533915721; Rule 144A Notes: Common Code 111731110 / ISIN US30050AAG85 / CUSIP 30050AAG8) (the "Notes") on the terms and subject to the conditions set forth in the consent solicitation memorandum dated 15 November 2022 (the "Consent Solicitation Memorandum"). Capitalised terms used, but not defined herein, shall have the meanings given to them in the Consent Solicitation Memorandum.
The Issuer notifies that, on 19 December 2022, (i) the Issuer and the New Trustee entered into the Deed of Appointment to effectuate the Appointment; and (ii) the Issuer and the New Trustee entered into the Supplemental Trust Deed to effectuate the Amendments. Accordingly, the Appointment and the Amendments have become effective and binding on all Noteholders with effect from that date.
The Issuer extends its gratitude for the support and cooperation demonstrated by investors which has been reflected in the successful results of the Consent Solicitation.
Questions and requests for assistance in connection with the Consent Solicitation should be directed to the Information and Tabulation Agent:
Limited liability company "Legal Capital Investor Services"
Address: 10 Krivokolenny lane, bldg. 6, Moscow 101000, Russia
Email: evraz@lcpis.ru
Phone: +7 495 122 05 17
Website: www.lcpis.ru
###
For further information:
Investor Relations
+7 495 232 1370
ir@evraz.com
-----------------------------------------------------------------------------------------------------------------------
ISIN: GB00B71N6K86, XS1533915721, XS1843443273, Category Code: MSCM TIDM: EVR LEI Code: 5493005B7DAN39RXLK23 OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State Sequence No.: 209693 EQS News ID: 1516489 End of Announcement EQS News Service =------------------------------------------------------------------------------------
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1516489&application_name=news
(END) Dow Jones Newswires
December 19, 2022 06:00 ET (11:00 GMT)
1 Year Evraz Chart |
1 Month Evraz Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions